Please assess the completion status of the following clinical trial:

Trial Title: Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Out-Patients of either sex aged ≥ 40 years~* Life-expectancy of 2 years at minimum~* Solid organ-transplant recipients who received a kidney (including pancreas), liver, lung, or heart transplant~* Patients treated for 5 years with an immunosuppressant medication~* Severe sun damage of the skin~* Multiple actinic keratoses (2-5 lesions) and/or multiple dysplastic naevi~* No present squamous cell carcinoma, basal cell carcinoma or malignant melanoma; but history of cutaneous/cutaneous invasive malignancy with restitutio ad integrum is allowed~* Patients who are able to understand and provide written informed consent to participate in the clinical trial (signed informed consent) according to ICH GCP~Exclusion Criteria:~* Non-Caucasian~* Absence of sun damage i.e. no signs of AK~* Multi-organ transplantation (exception: simultaneous transplantation of kidney and pancreas)~* Evidence of systemic infection, except viral hepatitis, at the time of recruitment~* Known or supposed systemic malignant tumour or systemic chemotherapy within the last 5 years prior to randomisation~* Patients participating in a clinical trial within the last four weeks before trial~* Patients treated with the antitumour/antiangiogenetic immunosuppressant sirolimus, respectively everolimus, or acitretin or any other systemic treatment for AK at the time of randomisation~* Patients treated with a topical drug for the AK at the time of randomisation (exception: excision or Cryotherapy for hyperkeratotic lesions are allowed)~* Change of the immunosuppression-treatment less than 3 months ago or planned~* Present or planned interferon therapy (in liver transplant patients with hepatitis B/C)~* Female patients with childbearing potential with a positive pregnancy test, breast feeding, or female patients with childbearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Sun Protection Measures (Type: ACTIVE_COMPARATOR): Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
- MD-3511356 (Type: EXPERIMENTAL): Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).

Based on this trial design, predict the completion outcome and termination type (if applicable).